Table 1. Main demographic, hematologic and biochemical characteristics of HIV-positive patients receiving atazanavir as part of their antiretroviral regimen.
| Parameters | All Patients(n = 240) | ATV/r 300/100 (n = 163) | ATV 400 (n = 77) |
|---|---|---|---|
| Male gender, % | 68% | 74% | 56% |
| Age, years | 46±11 | 45±10 | 49±13 |
| Naïve, % | 23% | 29% | 11% |
| ATV therapy, days | 901±870 | 846±886 | 1021±851 |
| HAART, % | 56% TDF-based | 60% TDF-based | 47% TDF-based |
| 24% ABC-based | 24% ABC-based | 22% ABC-based | |
| 10% RAL-based | 7% RAL-based | 18% RAL-based | |
| 10% others | 9% others | 13% others | |
| Weight, Kg | 69±14 | 70±14 | 68±14 |
| Body mass index, Kg/m2 | 24±4 | 24±4 | 24±4 |
| Creatinine, mg/dL | 0.9±0.4 | 0.9±0.3 | 0.9±0.7 |
| GGT, IU/L | 72±114 | 85±134 | 47±48 |
| ALT, IU/L | 47±49 | 49±53 | 42±40 |
| Total bilirubin, mg/dL | 2.1±1.6 | 2.3±1.7 | 1.7±1.2 |
| Total cholesterol, mg/dL | 187±46 | 191±48 | 178±39 |
| HDL cholesterol, mg/dL | 50±29 | 50±33 | 49±18 |
| Triglycerides, mg/dL | 167±124 | 179±132 | 143±104 |
| CD4, cells/mL | 593±247 | 572±249 | 639±239 |
| Pts with VL>100 cp/mL, % | 12% | 13% | 11% |
| HCV/HBV coinfection, % | 34% | 36% | 26% |
TDF: tenofovir; ABC: abacavir; RAL: raltegravir; GGT: gamma-glutamyltransferase; ALT: alanine aminotransferase; HCV: hepatitis C virus; HBV: hepatitis B virus; VL: viral load